Upgrades, downgrades, and outlook changes from major analysts.
Coverage of analyst actions including upgrades, downgrades, initiations, and price-target changes. This category tracks how institutional research influences market perception, momentum shifts, and short-term price behavior.
3,519 total articles
Goldman Sachs has reaffirmed a Neutral rating and a $223.00 price target on AbbVie as the company prepares to issue 2026 guidance alongside fourth-quarter 2025 results on February 4. The bank highlights investor debate over competitive pressures for Skyrizi and Rinvoq and notes management will stop updating mid-term guidance for those products. Gol…
JPMorgan raised its price target on Corning to $115 from $100 and kept an Overweight rating following the announcement of a multiyear supply agreement with Meta worth up to $6 billion. The pact is expected to support Meta’s data center expansion and spur additional investment in Corning’s North Carolina manufacturing footprint, including a new opti…
JPMorgan reaffirmed an Overweight rating on ASML and set a $1,518 price target, citing a substantial beat in fourth-quarter 2025 orders. The company reported record revenue and robust bookings that suggest stronger results ahead, while select valuation metrics indicate the stock may be rich relative to fair value.
H.C. Wainwright has reaffirmed a Buy rating and a $10.00 price target on Cardiff Oncology (CRDF) after the company disclosed updated clinical results from its CRDF-004 trial. The price target implies notable upside versus the current roughly $2 share price. Trial findings and upcoming regulatory and clinical milestones are informing near-term inves…
BMO Capital raised its price objective on Stride Inc. (NYSE: LRN) to $94 from $75 while retaining a Market Perform rating, citing fiscal second-quarter 2026 results that beat expectations largely due to a one-time gain. Management reaffirmed full-year revenue guidance and raised adjusted operating income expectations, even as core General Education…
H.C. Wainwright retained its Buy rating on Kazia Therapeutics and affirmed an $18.00 price target after the company released updated Phase 1b data for paxalisib in combination with pembrolizumab and chemotherapy in late-stage metastatic triple-negative breast cancer (TNBC). The small-cap biotech, trading at $7.15 with a market capitalization of $77…
F5 Networks reported first-quarter fiscal 2026 results that outperformed expectations, prompting an upward revision to full-year guidance while leaving some analysts cautious. The company beat revenue and EPS forecasts, posted strong margins and notable regional and segment gains, yet Needham preserved a Hold rating pending more sustained outperfor…
H.C. Wainwright reaffirmed its Buy rating and $60 price target for Maze Therapeutics (MAZE), citing a potential regulatory shortcut enabled by pediatric extrapolation for APOL1-mediated kidney disease. Multiple analysts have adjusted models and initiated coverage over recent weeks, reflecting heightened optimism ahead of a pivotal Phase 2 HORIZON r…
Evercore ISI raised its price target on Viridian Therapeutics to $45 from $44 while keeping an Outperform rating as the company approaches Phase 3 subcutaneous thyroid eye disease (TED) data expected in Q1 2026. The new target implies roughly 34% upside from the stock's then-current price of $33.54. The research house highlighted the importance of …
H.C. Wainwright raised its price target on Hecla Mining to $36.50 from $16.50 and kept a Buy rating after the miner reported stronger production across silver, gold, lead and zinc. The firm pointed to robust silver market demand and operational improvements, while market metrics show the stock trading at elevated multiples.
H.C. Wainwright has kept a Buy rating and a $16.00 price target on Aclaris Therapeutics (ACRS) after the company reported encouraging preclinical outcomes for ATI-2138 in a severe alopecia areata mouse model. The study, conducted by Dr. Angela Christiano at Columbia University, showed rapid and near-complete hair regrowth that outperformed Pfizer’s…
H.C. Wainwright increased its price target on Intellia Therapeutics to $25.00 from $15.00 and kept a Buy rating after the clinical hold on the MAGNITUDE-2 trial was lifted. Regulators allowed the Phase 3 study for hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) to resume under amended safeguards and an increased target enrollmen…
H.C. Wainwright has maintained a Buy rating and a $185.00 price target on Belite Bio (NASDAQ: BLTE) following the company’s announcement that the Phase 2/3 portion of the DRAGON II trial has completed enrollment of 60 adolescent subjects. The stock trades near its 52-week high after a strong year. Several other brokerages have initiated or reiterat…
Wedbush has reaffirmed an Outperform rating and a $350 price target on Apple ahead of the company’s fiscal first-quarter 2026 earnings report, arguing that recent holiday results and strategic initiatives could outpace current market expectations. The stock trades above InvestingPro’s Fair Value, and several other brokerages have issued divergent p…
H.C. Wainwright has reaffirmed a Buy rating and a $24.00 price target on Inventiva SA (NASDAQ: IVA) following a poster presentation at the Keystone Obesity Conference. The investment firm highlighted a unimolecular quintuple agonist described by researchers from Helmholtz Munich as supportive of Inventiva’s therapeutic approach combining GLP-1R and…
Canaccord Genuity has reiterated a Buy rating on Stride Inc. (LRN) and kept a $125.00 price target following the company’s fiscal second-quarter results. The target implies roughly 73% upside versus the current share price of $72.43. Stride delivered revenue and enrollment broadly in line with expectations while reporting profitability above consen…
UBS downgraded Nucor from Buy to Neutral while increasing its price target to $183 from $168. The decision reflects concerns that lower-cost steel imports from Southeast Asia and Brazil became economically viable in mid-October and that additional supply could hit U.S. markets starting in February. The move comes after Nucor outperformed peers sinc…
Barclays has begun coverage of Vertex Pharmaceuticals (NASDAQ: VRTX) with an Overweight rating and a $606 price target, highlighting the companys renal franchise, expected trial readouts in 2026, and potential revenue acceleration for the new acute pain therapy Journavx. Multiple other brokerages have recently raised ratings and price targets for …
UBS raised its target on Seagate Technology to $385 from $335 while retaining a Neutral rating, citing strong execution, expanding gross margins and progress on HAMR technology. The firm also increased EPS forecasts for fiscal 2026-2028 but warned that the stock may be pricing in a prolonged uptrend. Seagate recently posted better-than-expected fis…
Barclays initiated coverage of PTC Therapeutics (NASDAQ: PTCT) with an Overweight rating and a $119 price target, citing the commercial opportunity for the company’s phenylketonuria therapy Sephience and potential upside from Huntington’s disease programs. The target implies meaningful upside from the stock's recent trading level, and Barclays note…
BTIG reduced its price target for Roblox Corp. to $141 from $174 while maintaining a Buy rating ahead of the company’s fourth-quarter results due on February 5. The firm modestly raised bookings estimates for late-2025 and 2026, pointing to a split between weaker concurrent-user metrics and relatively stronger payer and monetization signals. Other …
Barclays initiated coverage of BridgeBio Pharma (BBIO) with an Overweight rating and an $80.00 price target, noting the company’s diversified late-stage portfolio and potential to scale. The move follows strong Attruby sales and preliminary revenue figures for 2025 and coincides with BridgeBio’s $550 million convertible note offering due 2033.
BofA Securities cut Plains All American (PAA) from Neutral to Underperform and kept a $19.00 price target, pointing to constrained Permian Basin production growth, a flat EBITDA forecast through the 2030s, and reduced upside from a lower FERC PPI adder. The bank also downgraded Plains GP Holdings on similar grounds.
Barclays has opened coverage on Bloom Energy (NYSE: BE) with an Equalweight rating and a $153 price objective. The bank cites the company’s rapid site commissioning, falling costs and average selling prices, and recent contract validations as demand drivers for its solid-oxide fuel cell technology, while warning that current market valuation alread…
BofA Securities upgraded Microchip Technology from Neutral to Buy and increased its price target to $95 from $78, citing improving recovery momentum and clearer visibility into demand. The firm boosted its CY26 and CY27 EPS estimates, highlighted the company’s significant industrial and aerospace exposure, and pointed to data-center-facing products…
